FOXQ1 and ductal breast carcinoma in situ: To determine which downstream pathways are mainly responsible for FGFR1 signaling stimulated FOXQ1 upregulation, DCIS-iFGFR1 cells were treated with vehicle or AP20187 in combination with or without different inhibitors of MEK, ERK, or AKT.